Table E3.
Sample distribution based on transbronchial biopsy evaluation∗
| Grade | Low | Anabolic | Intermediate | Catabolic | Firmi/Proteo/Actino dysbiosis | No dysbiosis | Bact dysbiosis | |
|---|---|---|---|---|---|---|---|---|
| Acute rejection | A0 | 28 (80) | 24 (80) | 57 (86.4) | 13 (81.3) | 20 (87) | 84 (81.5) | 24 (92.3) |
| A1 (minimal) | 5 (14.3) | 6 (20) | 7 (10.6) | 3 (18.7) | 3 (13.0) | 16 (15.6) | 1 (3.8) | |
| A2 (mild) | 2 (5.8) | 0 (0) | 2 (3) | 0 (0) | 0 (0) | 3 (2.9) | 1 (3.8) | |
| Airway inflammation | B0 | 31 (88.6) | 22 (84.6) | 57 (89.1) | 11 (78.6) | 13 (72.2) | 69 (84.1) | 20 (95.2) |
| B1-B2 (low grade) | 4 (11.4) | 4 (15.4) | 7 (10.9) | 3 (21.4) | 5 (27.8) | 13 (15.9) | 1 (4.8) |
Data presented as n (%) within each BAL cell gene expression profile or microbiota composition group.
Actino, Actinobacteria; Bact, Bacteroidetes; Firmi, Firmicutes; Proteo, Proteobacteria.
∗
Grading of pulmonary allograft rejection according to guidelines of the International Society for Heart and Lung Transplantation.E3